Note: results can be filtered by year and/or keyword. To filter on year, select the appropriate year from the drop down menu. To filter on keyword, enter relevant term into open box, select appropriate keyword, and click "filter".
Statements, Speeches, Letters
136th WHO Executive Board Agenda item 10.5 Global strategy and plan of action on public health, innovation and intellectual property Speaker: Katy Athersuch, Medical Access and Innovation Policy Advisor
Last updated 30 January 2015
136th WHO Executive Board Agenda item 10.4 Follow-up of the report of the Consultative Expert Working Group on Research and Development: Financing and Coordination Speaker: Katy Athersuch, Medical Access and Innovation Policy Advisor Médecins Sans Frontières is concerned by the lack of action by WHO and Member States in the face of clear and urgent recommendations in the CEWG report to address the collective under-investment in research and development to meet developing country health needs.
Last updated 30 January 2015
136th WHO Executive Board Agenda item 8.1 Antimicrobial resistanceSpeaker: Dr Arlene Chua, Antimicrobial Resistance Advisor
Last updated 29 January 2015
136th WHO Executive Board Agenda item 9.3 Global Vaccine Action PlanSpeaker: Nathalie Ernoult, Head of Advocacy, Regional and Francophone Médecins Sans Frontières welcomes the recommendations of the Strategic Advisory Group of Experts on the Global Vaccine Action Plan report. During the sixty-seventh World Health Assembly, over thirty Member States expressed concern over the high price of new vaccines, calling for WHO to develop strategies to increase affordability.
Last updated 27 January 2015
The European Union is currently negotiating new rules on European trademarks and are proposing language which will increase the risk of generic lifesaving medicines being stopped, seized and even destroyed while they are in transit in Europe en route to people in developing countries.
Last updated 3 December 2014
A letter to India's newly constituted IPR Think Tank, authored by MSF and signed by patient groups, public interest organisations, treatment providers and academia world-wide, raises critical issues around the intellectual property system in India. A particular area of concern is pharmaceuticals, as India is a key global supplier of affordable generic versions of drugs that otherwise would be out of reach for public health programmes, treatment providers and millions of people.
Last updated 1 December 2014
18 November 2014 The Tufts Center for the Study of Drug Development has just released its latest study on the average cost of developing a new drug. The average figure, released by Tufts CSDD, is US$2.588 billion ($2.56 billion).
Last updated 18 November 2014
Background Pharmaceutical company Bristol-Myers Squibb (BMS) has recently revealed a restrictive commercial strategy for sales of its new direct-acting antiviral (DAA) hepatitis C drug daclatasvir in developing countries. This new generation of drugs to treat hepatitis C is giving hope to the 185 million people infected with the disease today, as these drugs are expected to improve treatment and provide significantly higher chances of cure.
Last updated 3 November 2014
Last updated 22 October 2014
October 20th, 2014 To: President Jacob Zuma Minister of Trade and Industry Rob Davies Re: Promoting Access to Affordable Medicines in South Africa through Patent Law Reform
Last updated 20 October 2014